DON STEVEN DIZON
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology PROVIDENCE, RI NPI 1376573394
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology RI ABBVIE INC. All categories
General Payments — all program years on this page
$54,016.06
- Category: General Payments
- Program years: PY2018–2024
- Record count: 32
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $9,636.07 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $9,110.00 | 4 |
| Grant | $350.00 | 1 |
| Food and Beverage | $176.07 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $4,529.58 | 3 |
| PUMA BIOTECHNOLOGY, INC. | $2,560.00 | 1 |
| GlaxoSmithKline, LLC. | $1,500.00 | 1 |
| AstraZeneca UK Limited | $650.00 | 1 |
| Acerta Pharma LLC | $350.00 | 1 |
| Genentech USA, Inc. | $46.49 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1094038950 | AstraZeneca UK Limited | $650.00 | 06/11/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1103133739 | ABBVIE INC. | $4,400.00 | 10/29/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1103646640 | ABBVIE INC. | $27.35 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1103646642 | ABBVIE INC. | $102.23 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1104708535 | AstraZeneca Pharmaceuticals LP | $350.00 | 06/02/2024 | Grant | Undisputed | 01/23/2026 | View at CMS |
| 1113833985 | PUMA BIOTECHNOLOGY, INC. | $2,560.00 | 08/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1116638752 | GlaxoSmithKline, LLC. | $1,500.00 | 02/14/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1133002678 | Genentech USA, Inc. | $46.49 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.